Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: Epidemiology, Mechanisms, Diagnosis, Prevention, and Future Perspectives
SN Comprehensive Clinical Medicine · 13.07.2026 · 8 (1)
DOI: 10.1007/s42399-026-02540-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 13.07.2026. Verfasst von Naina Mohamed Pakkir Maideen und 4 weiteren Autor:innen. Die Arbeit nennt 88 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Maideen, N. M. P., Rashid, S. A., Balasubramanian, R., Vishwanathan, D., & Shanmugam, A. (2026). Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: Epidemiology, Mechanisms, Diagnosis, Prevention, and Future Perspectives. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02540-3
Vancouver
Maideen NMP, Rashid SA, Balasubramanian R, Vishwanathan D, Shanmugam A. Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: Epidemiology, Mechanisms, Diagnosis, Prevention, and Future Perspectives. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02540-3
BibTeX
@article{Maideen2026,
author = {Maideen, Naina Mohamed Pakkir and Rashid, Sulthan Al and Balasubramanian, Rajkapoor and Vishwanathan, Deepika and Shanmugam, Arun},
title = {Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: Epidemiology, Mechanisms, Diagnosis, Prevention, and Future Perspectives},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02540-3}
}
EUVIMED